Kidney International Reports最新文献

{"title":"A Within-Trial Economic Evaluation of a Patient Navigator Program in Children With CKD","authors":"Winnie Chen ,&nbsp;Germaine Wong ,&nbsp;Kirsten Howard ,&nbsp;Chandana Guha ,&nbsp;Anita van Zwieten ,&nbsp;Andrea N. Natsky ,&nbsp;Kylie-Ann Mallitt ,&nbsp;Rabia Khalid ,&nbsp;Anna Francis ,&nbsp;Allison Jaure ,&nbsp;Siah Kim ,&nbsp;Armando Teixeira-Pinto ,&nbsp;Amelie Bernier-Jean ,&nbsp;David W. Johnson ,&nbsp;Deirdre Hahn ,&nbsp;Elizabeth G. Ryan ,&nbsp;Hugh J. McCarthy ,&nbsp;Charani Kiriwandeniya ,&nbsp;Nicholas Larkins ,&nbsp;Patrina Caldwell ,&nbsp;Steve McTaggart","doi":"10.1016/j.ekir.2025.06.043","DOIUrl":"10.1016/j.ekir.2025.06.043","url":null,"abstract":"<div><h3>Introduction</h3><div>The NAVKIDS² trial was a patient navigation program for children and their caregivers living with chronic kidney disease (CKD) in Australia. We conducted a within-trial economic evaluation to describe the cost-effectiveness of patient navigation compared with standard care.</div></div><div><h3>Methods</h3><div>Cost and resource utilization data were prospectively collected over 6 months, from a health care funder perspective. Costs were reported in Australian dollars. Quality-of-life (QoL) data were collected from 0 to 6 months. Incremental cost-effectiveness ratios (ICERs) were reported as the additional cost/quality-adjusted life years (QALYs) gained.</div></div><div><h3>Results</h3><div>Over the 6-month period, total per-patient costs were higher in the patient navigation group than in those in the standard care group ($10,249 vs. $9368, respectively; <em>P</em> &lt; 0.001). There was no significant difference in mean health care costs between the 2 groups ($9848 vs. $9368, respectively, <em>P</em> = 0.98); however, the intervention group incurred an additional cost of $1075/person for the patient navigator. There was no significant difference in total QALYs over 6 months between patient navigation and standard care groups (0.33 vs. 0.30, respectively; <em>P</em> = 0.11). The ICER for the intervention group compared with usual care was $41,960/QALY gained with a wide 95% confidence interval (CI) (−$300,123 to +$769,958), indicating substantial uncertainty.</div></div><div><h3>Conclusion</h3><div>The economic evaluation found that the cost of patient navigators is relatively low compared with total health care costs; however, there is considerable uncertainty regarding the cost-effectiveness of the intervention. Further research is needed to evaluate long-term cost-effectiveness as well as potential impacts on health outcomes and health care utilization.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 3202-3212"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “The Role of von Willebrand Factor in the Pathogenesis of C3 Glomerulopathy” [Kidney International Reports Volume 10, Issue 6, June 2025, Pages 1929-1938]","authors":"Zixin Hua ,&nbsp;Yunying Chen ,&nbsp;Shasha Han ,&nbsp;Xiaojuan Yu ,&nbsp;Ying Tan ,&nbsp;Feng Yu ,&nbsp;Min Chen ,&nbsp;Minghui Zhao","doi":"10.1016/j.ekir.2025.06.045","DOIUrl":"10.1016/j.ekir.2025.06.045","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Page 3295"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reassessing Rituximab in Membranous Nephropathy: Efficacy, Limitations, and the Path Ahead","authors":"Anne-Els van de Logt ,&nbsp;Jack F.M. Wetzels","doi":"10.1016/j.ekir.2025.06.057","DOIUrl":"10.1016/j.ekir.2025.06.057","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 2909-2911"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144934105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reporting ADPK Disease Phenotypes on Abdominal Scans","authors":"Zhongxiu Hu ,&nbsp;Elizabeth G. Lane ,&nbsp;Grace C. Lo ,&nbsp;Jon D. Blumenfeld ,&nbsp;Daniil Shimonov ,&nbsp;James M. Chevalier ,&nbsp;Emily A. Schonfeld ,&nbsp;Danielle Brandman ,&nbsp;Martin R. Prince","doi":"10.1016/j.ekir.2025.06.046","DOIUrl":"10.1016/j.ekir.2025.06.046","url":null,"abstract":"<div><h3>Introduction</h3><div>Kidney and liver volumes from abdominal magnetic resonance imaging (MRI) and computed tomography (CT) scans are critical biomarkers recommended by Kidney Disease: Improving Global Outcomes (KDIGO) for autosomal dominant polycystic kidney disease (ADPKD) progression and response to therapy. The purpose of this study was to determine how often these biomarkers are included in radiology reports as well as their reproducibility.</div></div><div><h3>Methods</h3><div>Outside abdominal MRI (<em>n</em> = 102) and CT (<em>n</em> = 43) studies were reviewed retrospectively and independently by 2 observers for prevalence of reporting ADPKD-relevant findings with discrepancies resolved by 2 radiologists. These 2 radiologists independently reevaluated all examinations to assess interobserver reproducibility.</div></div><div><h3>Results</h3><div>Outside reports (<em>n</em> = 145; males: 46%; median age: 47 [interquartile range: 35–61] years) by 122 radiologists from 88 institutions included kidney volumes in only 30 (21%) reports. Out of 140 imaging examinations that included the entire liver, 1 (1%) outside report provided liver volume. Comparison of outside and study radiologists’ kidney volume measurements showed a median absolute difference of 15%, using the ellipsoidal method and 8% using model-assisted contouring. Additional positive findings not mentioned in 145 outside reports included umbilical hernia (<em>n</em> = 44), hepatic steatosis (<em>n</em> = 3), inguinal hernia (<em>n</em> = 4), pancreatic cyst (<em>n</em> = 6) and severe inferior vena cava (IVC) compression by cysts (<em>n</em> = 2).</div></div><div><h3>Conclusion</h3><div>Radiologists report reliably on complex cysts, calcifications, ascites, and abdominal aortic aneurysms in ADPKD. However, the clinical utility of these reports can be improved more reliably by including kidney volume and other important imaging features of ADPKD recommended by clinical guidelines.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 2967-2976"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Systematic Review of Sleep Hygiene Strategy in CKD","authors":"Ginger Chu ,&nbsp;Fiona Yu ,&nbsp;Ya-Fang Ho ,&nbsp;Chia-Ter Chao ,&nbsp;Andrea K. Viecelli","doi":"10.1016/j.ekir.2025.06.018","DOIUrl":"10.1016/j.ekir.2025.06.018","url":null,"abstract":"<div><h3>Introduction</h3><div>Sleep hygiene strategies are often encouraged in people with chronic kidney disease (CKD). We aimed to summarize the existing evidence on sleep hygiene strategies in this population.</div></div><div><h3>Methods</h3><div>We searched 4 electronic databases (MEDLINE, EMBASE, CINAHL, and PsycINFO) up to July 2024. Studies of any design were eligible if they reported sleep hygiene strategies and sleep outcomes for adults with CKD. We extracted data using standardized tools and synthesized the results into each component of the sleep hygiene strategy. The effectiveness of each sleep hygiene strategy was summarized using meta-analysis and in a narrative manner.</div></div><div><h3>Results</h3><div>Thirty-eight articles were included. Most studies (45%) focused on bedtime activity, with exercise (standardized mean difference [SMD]: −1.05, 95% confidence interval [CI]: −2.03 to −0.07) and relaxation techniques (SMD: −1.54, 95% CI: −2.34 to −0.73) showing promising effects on sleep quality. However, the timing of these strategies varied, limiting the ability to generalize these strategies in relation to bedtime activity. Few studies (18%) demonstrated positive effects of sleep hygiene education (SMD: −0.82, 95% CI: −1.57 to −0.63), particularly when delivered as part of cognitive behavior therapy (CBT). Mixed results were found regarding the impact of alcohol, caffeine, and cigarettes on sleep disturbances and sleep disorders. Limited studies have been conducted on bedroom environment, sleep patterns, and daytime napping in patients with CKD.</div></div><div><h3>Conclusion</h3><div>This review showed that sleep hygiene education can be a useful strategy for improving sleep in people with CKD. Exercise and relaxation techniques may reduce sleep disturbances; however, further research is necessary to determine the optimal timing for these activities.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 3006-3022"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Steroid Avoidance With Low-Dose Tacrolimus is Safe and Effective in the Long-Term for Kidney Transplant Recipients","authors":"Jana Ekberg ,&nbsp;Anna-Elisabeth Aagaard Enevoldsen ,&nbsp;Carin Wallquist ,&nbsp;Karin Skov ,&nbsp;Bente Jespersen ,&nbsp;Per Lindnér ,&nbsp;Seema Baid-Agrawal","doi":"10.1016/j.ekir.2025.06.016","DOIUrl":"10.1016/j.ekir.2025.06.016","url":null,"abstract":"<div><h3>Introduction</h3><div>In our previous multicenter, open-label, randomized controlled trial (RCT), the SAILOR study, we reported good feasibility, safety, and efficacy of steroid avoidance (SA) at 2 years in immunologically low-risk kidney transplant recipients. A total of 222 participants were randomized to either antithymocyte globulin (ATG) induction + low-dose tacrolimus + mycophenolate mofetil (MMF) or basiliximab induction + low-dose tacrolimus + MMF + prednisolone. Long-term results are needed to confirm the extended safety and efficacy of the SA protocol beyond the short- to medium-term follow-up seen in current reports using low-dose tacrolimus.</div></div><div><h3>Methods</h3><div>In the SAILOR follow-up observational study, we collected clinical data of 215 participants of the original SAILOR trial at 1, 2, 5 years, and at the last follow-up.</div></div><div><h3>Results</h3><div>The mean follow-up time postrandomization was 7.3 years. Death-censored graft survival (91.8 vs. 93.1%, <em>P</em> = 0.88), patient survival (88 vs. 93%, <em>P</em> = 0.32), cumulative incidence of biopsy-proven rejection (19.8% vs. 16.3%, <em>P</em> = 0.6), and kidney function (estimated glomerular filtration rate [eGFR]: 50.8 vs. 54 ml/min per 1.73 m², <em>P</em> = 0.27) were similar in the 2 arms. Cumulative incidence of posttransplantation diabetes mellitus in per-protocol population was significantly lower in the steroid-avoidance arm. Serious infections requiring hospitalization, and malignancies did not differ significantly. Two-thirds of participants in the SA arm remained on the steroid-free protocol at the end of follow-up.</div></div><div><h3>Conclusion</h3><div>SA proved to be safe and effective in patients with low immunological risk for up to 7 years following kidney transplantation. Our findings provide robust evidence supporting SA strategy with low-dose tacrolimus without compromising outcomes even at the extended 7-years follow up.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 3102-3112"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Protective Effects of SGLT-2 Inhibitors Against Postoperative Acute Kidney Injury in Type 2 Diabetes","authors":"Seung Min Song ,&nbsp;Minji Kim ,&nbsp;Minyoung Jang ,&nbsp;Minhyung Kim ,&nbsp;Kyungho Lee ,&nbsp;Junseok Jeon ,&nbsp;Sang-Man Jin ,&nbsp;Hye Ryoun Jang ,&nbsp;Wooseong Huh ,&nbsp;Jung Eun Lee","doi":"10.1016/j.ekir.2025.06.036","DOIUrl":"10.1016/j.ekir.2025.06.036","url":null,"abstract":"<div><h3>Introduction</h3><div>Despite concerns about the potential of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) to cause acute kidney injury (AKI), recent studies have shown that patients with diabetes on long-term SGLT-2i have lower rates of AKI-related hospitalizations and dialysis. We aimed to assess the real-world preventive effects of SGLT-2i on the risk of postoperative AKI.</div></div><div><h3>Methods</h3><div>We conducted a retrospective study on patients with diabetes who underwent a major surgery at a tertiary hospital in Korea from 2013 to 2023 (<em>n</em> = 5527). We compared patients receiving SGLT-2i with those receiving dipeptidyl peptidase-4 inhibitors (DPP-4i) before surgery to evaluate the development of AKI within 7 days after surgery. A 1:3 propensity score matching was performed to adjust for 10 potential confounders.</div></div><div><h3>Results</h3><div>Before matching, the mean age was 67.5 years, with males comprising 66.3% of the cohort. In the matched cohort, the incidence of postoperative AKI was 11.9% in patients on SGLT-2i and 15.1% in those on DPP-4i (<em>P</em> = 0.026). In a multivariable logistic regression analysis adjusted for various risk factors, the use of SGLT-2i was associated with a 31% reduction in the risk of postoperative AKI (odds ratio [OR]: 0.699; 95% confidence interval [CI]: 0.528–0.918; <em>P</em> = 0.011). Subgroup analyses demonstrated a significant protective effect of SGLT-2i in high-risk populations, particularly in patients with heart failure undergoing cardiovascular surgery, where the incidence of AKI increased to 54%, in which SGLT-2i reduced the risk of AKI by up to 57% (OR: 0.431; 95% CI: 0.205–0.889; <em>P</em> = 0.024). However, the SGLT-2i group experienced a higher incidence of mild diabetic ketoacidosis (DKA) than the DPP-4i group (0.8% vs. 0%; <em>P</em> &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>The use of SGLT-2i was independently associated with a lower risk of postoperative AKI than the use of DPP-4i in patients with type 2 diabetes, particularly in high-risk groups such as those with heart failure undergoing cardiovascular surgery. These findings suggest that SGLT-2i may have a role in perioperative AKI prevention in patients with diabetes, although careful monitoring for DKA is advised.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 3181-3191"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144934027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemodiafiltration Attenuates NETosis Compared With High-Flux Hemodialysis in End-Stage Kidney Disease Patients","authors":"Lital Remez-Gabay ,&nbsp;Olga Vdovich ,&nbsp;Faten Y. Andrawes Barbara ,&nbsp;George Jiries ,&nbsp;Etty Kruzel-Davila","doi":"10.1016/j.ekir.2025.06.002","DOIUrl":"10.1016/j.ekir.2025.06.002","url":null,"abstract":"<div><h3>Introduction</h3><div>Patients with chronic kidney disease (CKD) and diabetes mellitus face a heightened risk of cardiovascular complications and infections, potentially exacerbated by dysregulated NETosis. Given the superior survival rates observed with hemodiafiltration (HDF) over high-flux hemodialysis (HD; HFHD) and the documented NETosis dysregulation in HD and in patients with diabetes mellitus, this study aimed to investigate the impact of dialysis modality on NETosis activity in patients on HD, stratified by diabetes status.</div></div><div><h3>Methods</h3><div>A total of 20 patients on HD (10 with diabetes, 10 without diabetes) undergoing HDF treatment were recruited. Blood samples were collected before and after HDF. After transition to HFHD treatment, blood samples were taken again after 1 and 3 weeks of HDFD treatment. Neutrophils were isolated, stimulated with phorbol-12-myristate-13-acetate, and stained for the following NETosis markers: peptidyl arginine deiminase 4 (PAD4), neutrophil elastase (NE), myeloperoxidase (MPO), histone H3, and double-stranded DNA (dsDNA). Data were acquired using a flow cytometer. In addition, serum levels of citrullinated histone H3 (citH3), MPO, and NE were measured using enzyme-linked immunosorbent assay.</div></div><div><h3>Results</h3><div>Our results demonstrate a significant increase in NETosis activation and markers after HFHD treatment compared with HDF treatment. NETosis markers significantly increased in serum after 3 weeks of HFHD treatment. In addition, significantly lower NETosis markers were observed in patients with diabetes than in patients without diabetes.</div></div><div><h3>Conclusion</h3><div>The increase in NETosis markers after 3 weeks of HFHD compared with HDF highlights the role of HDF in mitigating dysregulated NETosis. Further research is needed to explore differences in NETosis profiles across patient populations and assess their clinical implications based on dialysis modality.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 3070-3080"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ethical Considerations for Research in CKD of Unknown Etiology: Reflections From an Ethics Panel at the Fourth International Workshop on CKD of Unknown Etiology","authors":"Nathan H. Raines ,&nbsp;Marta Avellan ,&nbsp;Jesica Candanedo ,&nbsp;Berta Sam ,&nbsp;Madeleine K. Scammell ,&nbsp;Catharina Wesseling ,&nbsp;Julia Wijkstrom ,&nbsp;Vidhya Venugopal ,&nbsp;Marvin González-Quiroz ,&nbsp;Peter Rohloff","doi":"10.1016/j.ekir.2025.06.053","DOIUrl":"10.1016/j.ekir.2025.06.053","url":null,"abstract":"<div><div>Chronic kidney disease (CKD) of unknown etiology (CKDu) is a form of tubulointerstitial kidney disease predominantly affecting impoverished agricultural communities in the global tropics, with major hotspots identified in Mesoamerica and South Asia. From February 14 to 16, 2024, the Consortium for the Epidemic of Nephropathy in Central America and Mexico (CENCAM) hosted the Fourth International Workshop on CKDu in Antigua, Guatemala. The workshop hosted &gt; 100 experts of CKDu from Central America and around the world. For the first time, a panel discussion was dedicated to the ethical challenges of conducting CKDu research and interventions in low-resource communities affected by the disease. Epidemiologists, nephrologists, and scientists with expertise in community-based research and bioethics on the panel identified several key ethical considerations, primarily centered on researcher interactions with affected communities or other CKDu stakeholders. These included aligning research priorities, study designs, consent procedures, and the return of results with the needs and concerns of CKDu-affected communities; fostering equitable North-South collaboration in CKDu research; and ensuring that research findings are translated into meaningful actions to help mitigate the disease’s impact, even as scientific understanding remains incomplete. The panel emphasized that affected communities, local health care systems, regional governments, and international researchers are all critical stakeholders in CKDu research. Ongoing discussion is essential to ensure that ethical considerations remain centered in response to emerging challenges and insights related to CKDu.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 2937-2942"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Salt and Volume Homeostasis in Patients Receiving Hemodialysis: Novel Considerations for Future Clinical Trials","authors":"Gerren Hobby ,&nbsp;Benjamin Lazarus","doi":"10.1016/j.ekir.2025.07.026","DOIUrl":"10.1016/j.ekir.2025.07.026","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 2912-2913"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}